Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib for painful crisis reduction in refractory sickle cell anemia
IRCT20131106015305N2Phase 2Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in sickle cell anemia (SCA), sponsored by Shiraz University of Medical Sciences. Primary endpoints: Number of painful crises per year in each patient and Total number of hospitalizations due to painful crisis per year per patient. Started Apr 2014; status: completed.
02
Drugs
03
Conditions
sickle cell anemia (SCA)
Beyond the preview
Go deeper on IRCT20131106015305N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20131106015305N2.